The firm’s global healthcare team co-lead thinks many bigger firms are anxious not to miss the next healthcare consolidation trend so are increasingly looking to the mid-market for deals.
More than 100 healthcare professionals gathered at the Westin Times Square in New York this week for Private Healthcare Investor’s inaugural investor forum. Here are some of the key takeaways.
Biotech stood alone in the first quarter as the only sector to achieve US venture-backed IPOs. Why is it so resilient?
The need for fresh funding has never been greater, so why aren’t more private equity firms investing in the UK’s National Health Service?
The consolidation of specialist medical clinics is one of the hottest strategies for North American healthcare-focused private equity firms.
Speciality pharma is no longer simply the domain of specialist private equity investors.
Recent interviews with Bain, TVM and Leapfrog provide insight into how fund managers are approaching the plethora of healthcare investment opportunities globally.
A growing but fragmented market and increasingly onerous regulation have created conditions ripe for US dermatology clinic consolidation.
Why medical device deals are appealing to private investors looking to invest in public equities.
The big private equity firm couldn’t see the asset it wanted – so the firm built one instead.